We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+37.89%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.91B
AUM Growth
+$772M
Cap. Flow
-$38.9M
Cap. Flow %
-0.99%
Top 10 Hldgs %
65.59%
Holding
46
New
5
Increased
6
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
XOMA
Xoma
XOMA
+$203M
2
QTTB icon
Q32 Bio
QTTB
+$19.6M
3
SGMT icon
Sagimet Biosciences
SGMT
+$17M
4
RVMD icon
Revolution Medicines
RVMD
+$15.8M
5
ABSI icon
Absci
ABSI
+$13.3M

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$140M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$53.1M
3
CMPX icon
Compass Therapeutics
CMPX
+$41.1M
4
PVLA
Palvella Therapeutics
PVLA
+$35M
5
SEPN
Septerna Inc
SEPN
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.14%
3 Miscellaneous 0.01%

No holdings matched the selected filter criteria.

1 2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2026 Portfolio in Review

As of Q2 2026, BVF Inc held 46 positions worth $3.91B, up 25% from $3.14B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

BVF Inc's Q2 2026 filing shows 5 new, 6 increased, 9 reduced and 2 closed positions. Its largest new stake was Q32 Bio: 2,350,000 shares worth $29.9M. The largest sale was Kymera Therapeutics, an estimated $140M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • BVF Inc's largest Q2 2026 buy was Q32 Bio: 2,350,000 shares worth $29.9M.
  • BVF Inc added most to Xoma in Q2 2026, an estimated $203M increase.
  • BVF Inc's biggest Q2 2026 reduction was Kymera Therapeutics, cutting an estimated $140M.
  • BVF Inc fully exited Compass Therapeutics in Q2 2026, selling an estimated $41.1M.
  • BVF Inc's ten largest holdings make up 66% of its $3.91B portfolio in Q2 2026.
  • BVF Inc opened 5 new positions and closed 2 in Q2 2026.
  • BVF Inc's portfolio value rose 25% quarter-over-quarter to $3.91B.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.